Article

Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture.

From the Departments of Stem Cell Transplantation and Cellular Therapy (M.L., I. McNiece, S.N.R., A.A., R.S., I.K., P.K., S.P., U.P., C.H., R.C., J.J.M., R.B.J., Y.N., B.S.A., N.S., B.O., M.H.Q., M.K., G.R., S.C., D.B., I. Maewal, E.J.S.), Biostatistics (M.M.), and Pediatrics (L.J.N.C., L.W.), University of Texas M.D. Anderson Cancer Center, and the Center for Cell and Gene Therapy, Baylor College of Medicine (C.B.) - both in Houston
New England Journal of Medicine (Impact Factor: 54.42). 12/2012; 367(24):2305-2315. DOI: 10.1056/NEJMoa1207285
Source: PubMed

ABSTRACT Background Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells. Methods We studied engraftment results in 31 adults with hematologic cancers who received transplants of 2 cord-blood units, 1 of which contained cord blood that was expanded ex vivo in cocultures with allogeneic mesenchymal stromal cells. The results in these patients were compared with those in 80 historical controls who received 2 units of unmanipulated cord blood. Results Coculture with mesenchymal stromal cells led to an expansion of total nucleated cells by a median factor of 12.2 and of CD34+ cells by a median factor of 30.1. With transplantation of 1 unit each of expanded and unmanipulated cord blood, patients received a median of 8.34×10(7) total nucleated cells per kilogram of body weight and 1.81×10(6) CD34+ cells per kilogram - doses higher than in our previous transplantations of 2 units of unmanipulated cord blood. In patients in whom engraftment occurred, the median time to neutrophil engraftment was 15 days in the recipients of expanded cord blood, as compared with 24 days in controls who received unmanipulated cord blood only (P<0.001); the median time to platelet engraftment was 42 days and 49 days, respectively (P=0.03). On day 26, the cumulative incidence of neutrophil engraftment was 88% with expansion versus 53% without expansion (P<0.001); on day 60, the cumulative incidence of platelet engraftment was 71% and 31%, respectively (P<0.001). Conclusions Transplantation of cord-blood cells expanded with mesenchymal stromal cells appeared to be safe and effective. Expanded cord blood in combination with unmanipulated cord blood significantly improved engraftment, as compared with unmanipulated cord blood only. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00498316 .).

Download full-text

Full-text

Available from: Laurence Cooper, Jun 30, 2015
0 Followers
 · 
256 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell dose is a major limitation for umbilical cord blood (UCB) transplantation since units containing a minimum of 2.5 x 10(7) total nucleated cells (TNC)/ kilogram patient body weight are frequently not available. The transplantation of two partially HLA-matched UCB units has been adopted as a simple approach for increasing the TNC. We sought to determine whether the relative safety and efficacy of this approach was comparable to a single UCB transplant. Included are adults with acute leukemia transplanted with one (n=106) or two UCB units (n=303). All UCB units for single UCB transplants contained TNC ≥2.5 x 10(7)/kg. For double UCB transplants, the total TNC for units 1 and 2 were greater than 2.5 x 10(7)/kg but in about half of these transplants, one of the two units contained <2.5 x 10(7) TNC/kg. Adjusting for factors associated with outcomes, risks of neutrophil recovery (OR 0.83, p=0.59), transplant-related mortality (HR 0.91, p=0.63), relapse (HR 0.90, p=0.64) and overall mortality (HR 0.93, p=0.62) was similar after double UCB and adequate dose single UCB transplants. These data support double UCB unit transplantation for acute leukemia when an adequately dosed single UCB unit is not available thereby extending access to nearly all patients.
    Blood 12/2012; 121(5). DOI:10.1182/blood-2012-08-449108 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P=0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P=0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Third-party UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.Bone Marrow Transplantation advance online publication, 11 February 2013; doi:10.1038/bmt.2013.7.
    Bone marrow transplantation 02/2013; 48(8). DOI:10.1038/bmt.2013.7 · 3.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A preparative regimen of reduced intensity that can reliably engraft cord blood (CB) and be used as an alternative to either high-dose myeloablative or non-myeloablative conditioning is needed. We evaluated double-unit CB transplantation (CBT) in 30 patients (median age 56 years range 18-69) with acute leukemia or myelodysplasia using a regimen of cyclophosphamide 50 mg/kg, fludarabine 150 mg/m(2), thiotepa 10 mg/kg, and 400 cGy total body irradiation with cyclosporine-A/ mycophenolate mofetil immunosuppression. Ninety-seven percent of patients engrafted at a median of 26 days (range 13-43), and 93% of patients had recovered platelets by day 180. Grade II-IV acute graft-versus-host disease (GVHD) incidence was 67% at day 180, and chronic GVHD was 10% at 1-year. Transplant-related mortality (TRM) was 20% at day 180, and relapse was 11% at 2-years. Overall, 2-year disease-free survival (DFS) is 60% at 2-years. There was a hierarchy in DFS according to the Sorror comorbidity score: the 11 patients (median age 55 years) with a score of 1 had a 2-year DFS of 82% compared with 62% in the 9 patients (median age 51 years) with a score of 2-3, and 40% in the 11 patients (median age 58 years) with a score of 4-5 (p = 0.13). This reduced intensity regimen combined with double-unit CBT reliably facilitates sustained donor engraftment without anti-thymocyte globulin. While other approaches are needed in patients with high comorbidity scores, this regimen is highly effective in patients > 50 years who are otherwise reasonably fit. It also represents a promising alternative to high-dose conditioning in younger patients.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 02/2013; 19(5). DOI:10.1016/j.bbmt.2013.02.007 · 3.35 Impact Factor